A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

Official title

A Phase 1 Open-Label, Multicenter Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HBM7020 in Healthy Adult Participants and Adults With Seropositive Autoimmune Disease

Overview

This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).

Interventions

• Drug HBM7020
  Liquid formulation, administered through intravenous infusion

Primary outcome measures

• Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48 [Time frame: Up to Week 48]
• Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related Infection [Time frame: Up to Week 24]
• Number of Participants With Dose limiting AE Evaluation During Dose Escalation [Time frame: Up to Day 15]
• Number of Participants With Clinically Significant Changes in Vital Signs [Time frame: Up to Week 24]
• Number of Participants With Clinically Significant Changes in Physical Examination Findings [Time frame: Up to Week 24]
• Change From Baseline in Serum Interleukin-6 (IL-6) [Time frame: Up to Week 20]
• Change From Baseline in Serum Tumour Necrosis Factor-Alpha (TNF-α) [Time frame: Up to Week 20]
• Change From Baseline in Serum Interferon-Gamma (IFN-γ) [Time frame: Up to Week 20]
• Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP) [Time frame: Up to Week 20]
• Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR) [Time frame: Up to Week 20]

Secondary outcome measures (5)

• Area Under the Concentration-Time Curve From Time Zero to Last Observable Concentration (AUCt) of HBM7020 [Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)]
• Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of HBM7020 [Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)]
• Maximum Observed Plasma Concentration (Cmax) of HBM7020 [Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)]
• Time to Maximum Observed Plasma Concentration (tmax) of HBM7020 [Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)]
• Number of Participants With Anti-Drug Antibodies (ADA) to HBM7020 [Time frame: Up to Week 24]

Eligibility criteria

Key Inclusion Criteria for Healthy Participants (Part 1)

• Participants who are of non-childbearing potential or are using acceptable contraception.
• Body mass index (BMI) and body weight within an acceptable range.
• Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.

Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 1)

• BMI and body weight within an acceptable range.
• Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.

Key Disease-Specific Inclusion Criteria for Patient Participants (Part 1)

• Confirmed autoimmune disease with appropriate supporting autoantibody findings.
• Stable background therapy prior to dosing.
• Active moderate to severe disease consistent with protocol-defined disease activity criteria for:

• Systemic lupus erythematosus (SLE)
• Systemic sclerosis (SSc)
• Rheumatoid arthritis (RA)
• Sjögren's disease (SjD)

Key Inclusion Criteria for Rescreening Participants (Part 2)

• Meets Part 1 disease-agnostic inclusion criteria.
• Stable background autoimmune therapy prior to dosing.
• Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.

Key Exclusion Criteria for Parts 1 and 2

• Pregnant or breastfeeding participants.
• Recent vaccination within protocol-defined timelines.
• Clinically significant medical history or abnormal physical examination findings.
• Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
• Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
• Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07649265 · 365-201-00001

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗